美国视角下重型血友病B基因治疗的成本效果微模拟研究
该研究构建微模拟Markov模型,比较AAV介导的FIX-Padua基因治疗与美国重型血友病B患者按需替代治疗和初级预防的成本效果。以15万美元/质量调整生命年为阈值,基因治疗比两种替代方案更具成本效果,概率敏感性分析中92%的模拟认为其具有成本效果。
要点
- 以15万美元/QALY为阈值,基因治疗较按需治疗和预防更具成本效果。
- 单因素敏感性分析中102种情景有10种基因治疗不具成本效果。
- 概率敏感性分析中92%的模拟显示基因治疗具有成本效果。
核心结论
- 基于详细的模拟输入和假设,基因治疗对重型血友病B患者比按需治疗和预防更具成本效果。
研究设计与样本
- 构建微模拟Markov模型,比较AAV介导的FIX-Padua基因治疗与按需FIX替代治疗及初级FIX预防(含标准或延长半衰期产品)。
- 研究视角为美国第三方支付方,时间范围为18岁至死亡,成本和效用参数来源于已发表数据。
主要发现
- 以15万美元/QALY为阈值,基因治疗比两种替代方案更具成本效果。
- 单因素敏感性分析显示102种情景中10种基因治疗不具成本效果。
- 在假设浓缩因子折扣价为美国批发采购成本20%的情景下,基因治疗仍具成本效果。
- 概率敏感性分析估计在15万美元/QALY阈值下,92%的模拟中基因治疗具有成本效果。
关键数值与推荐
- 成本效果阈值为15万美元/QALY。
临床怎么用
- 可为美国支付方评估重型血友病B基因治疗的经济性提供参考。
- 提示基因治疗在特定阈值下可能优于按需治疗和预防策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adeno-associated virus (AAV)-mediated gene therapy is a novel treatment promising to reduce morbidity associated with hemophilia. Although multiple clinical trials continue to evaluate efficacy and safety, limited cost-effectiveness data have been published. This study compared the potential cost-effectiveness of AAV-mediated factor IX (FIX)-Padua gene therapy for patients with severe hemophilia B in the United States vs on-demand FIX replacement and primary FIX prophylaxis, using either standard or extended half-life FIX products. A microsimulation Markov model was constructed, and transition probabilities between health states and utilities were informed by using published data. Costs were aggregated by using a microcosting approach. A time horizon from 18 years old until death, from the perspective of a third-party payer in the United States, was conducted. Gene therapy was more cost-effective than both alternatives considering a $150 000/quality-adjusted life-year threshold. The price for gene therapy was assumed to be $2 000 000 in the base case scenario; however, one of the 1-way sensitivity analyses was conducted by using observed manufacturing, administration, and 5-year follow-up costs of $87 198 for AAV-mediated gene therapy vector as derived from the manufacturing facility and clinical practice at St Jude Children's Research Hospital. One-way sensitivity analyses revealed 10 of 102 scenarios in which gene therapy was not cost-effective compared with alternative treatments. Notably, gene therapy remained cost-effective in a hypothetical scenario in which we estimated that the discounted factor concentrate price was 20% of the wholesale acquisition cost in the United States. Probabilistic sensitivity analysis estimated gene therapy to be cost-effective at 92% of simulations considering a $150 000/quality-adjusted life-year threshold. In conclusion, based on detailed simulation inputs and assumptions, gene therapy was more cost-effective than on-demand treatment and prophylaxis for patients with severe hemophilia B.
引用
- Bolous NS, Chen Y, Wang H, et al. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood. 2021. PMID: 33895800. doi:10.1182/blood.2021010864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。